Fate Therapeutics. has filed a patent for methods and compositions to enhance therapeutic effects using genomically engineered iPSC-derived cells. The patent also includes a claim for a chimeric fusion receptor without ER retention or endocytosis signals. GlobalData’s report on Fate Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Fate Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Fate Therapeutics, T-cell culturing was a key innovation area identified from patents. Fate Therapeutics's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Genetically engineered ipsc-derived cells for enhanced therapeutic effects

Source: United States Patent and Trademark Office (USPTO). Credit: Fate Therapeutics Inc

A chimeric fusion receptor (CFR) has been described in a filed patent (Publication Number: US20240033355A1). The CFR comprises an ectodomain, a transmembrane domain, and an endodomain, without any endoplasmic reticulum (ER) retention signals or endocytosis signals. The ectodomain initiates signal transduction upon binding to a selected agonist, while the endodomain contains signaling domains that activate specific pathways to enhance cell therapeutic properties. The CFR is cell surface presented, with reduced internalization and surface downregulation. The endodomain and ectodomain are modular, allowing for switchability based on binding specificity of the agonist or selected signaling pathways for regulation.

Furthermore, the CFR's ectodomain can be derived from various extracellular portions of signaling proteins such as CD3e, CD3?, CD3d, CD28, and others. The selected agonist, which can be an antibody or an engager, binds specifically to the ectodomain of the CFR. The patent also covers the use of the CFR in various therapeutic applications, including in combination with other therapeutic agents like checkpoint inhibitors, antibodies, and cytokines. The method of manufacturing derivative effector cells from genetically engineered iPSCs, as well as the therapeutic use of cells comprising the CFR for treating diseases or conditions, are also detailed in the patent claims. Overall, the patent outlines a novel approach to developing chimeric fusion receptors with potential applications in adoptive cell therapy for various medical conditions.

To know more about GlobalData’s detailed insights on Fate Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies